Kingsoft Cloud Holdings Limited vs Revvity Inc — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 6.3× Kingsoft Cloud Holdings Limited's market cap, and Revvity Inc pays a 0.18% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Revvity Inc for 12 Days on average.
| KC | RVTY | |
|---|---|---|
Market Cap | $2.71B | $16.98B |
Volume | 1,993,765 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $18.21 | $157.36 |
52-Week Low | $8.58 | $82.26 |
Typical Hold Time | 12 Days | 12 Days |
Enterprise Value | $3.03B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.33% with bearish technical indicators but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. Despite negative net margins, gross margins improved significantly to 15.05% as AI cloud services drive growth. Cash flow from operations reached $3.8 billion in 2025, though 2026 projections show negative net cash flow.
KC presents a compelling turnaround story with AI-driven growth potential, trading at attractive valuation multiples (P/S: 1.58, EV/EBITDA: 2,203). However, persistent losses and negative cash flow projections for 2026 pose significant execution risks. The 70% analyst buy rating and 60% upside potential must be weighed against the bearish technical picture and competitive cloud market dynamics.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →